Short-Term and Long-Term Clinical Evaluation of a Non-Amphetaminic Anorexiant (Mazindol) in the Treatment of Obesity

Abstract

The effectiveness and tolerance of a non-amphetaminic anorexiant drug has been evaluated in a short-term and in a long-term clinical trial in simple obesity and in refractory obesity. In the short-term 'crossover' trial, a more evident effectiveness and tolerance result when the anorexiant is given in a late phase of treatment. The association of an anorexiant drug with the hypocaloric diet was seen to be effective in the treatment of so-called refractory obesity. In the evaluation of the long-term treatment it is seen that weight loss is greater and remains so farr longer periods in patients receiving anorexiant, as compared to controls. This is related to a better maintenance of a restricted calorie regimen. Mazindol did not affect the improvement of glucose tolerance and insulin secretion which follows the weight reduction.

Long-term Pharmacotherapy of Obesity 2000

“…In patients with stable cardiac disease, mazindol treatment has been associated with untoward cardiac events (3 episodes of atrial fibrillation and 2 of syncope in 15 patients receiving mazindol for 12 weeks) 36 and significant withdrawls owing to adverse effects. 37,38 The longest report of mazindol treatment was an open-label observation in which 11 patients treated intermittently for 12.5 months with mazindol, 1 mg/d, lost 14 kg (PϽ.05) compared with a loss of 10 kg in a historical control group treated with diet alone. 37 Other long-term data on mazindol are limited to an uncontrolled observation of 12-kg weight loss with 60 weeks' treatment and a higher rate of maintained weight loss for 1 year following a very-low-calorie diet with (53%) than without (20%) mazindol treatment.…”

“…37,38 The longest report of mazindol treatment was an open-label observation in which 11 patients treated intermittently for 12.5 months with mazindol, 1 mg/d, lost 14 kg (PϽ.05) compared with a loss of 10 kg in a historical control group treated with diet alone. 37 Other long-term data on mazindol are limited to an uncontrolled observation of 12-kg weight loss with 60 weeks' treatment and a higher rate of maintained weight loss for 1 year following a very-low-calorie diet with (53%) than without (20%) mazindol treatment. 38 Overall, mazindol's efficacy has not been assessed in a longterm, blinded, placebo-controlled trial and its safety in cardiac patients is suspect.…”

Effects of Dietary Intake of Japanese Mushrooms on Visceral Fat Accumulation and Gut Microbiota in Mice

“…To prevent or reduce obesity, the imbalance between energy intake and expenditure needs to be addressed by improving dietary habits and/or increasing physical activity, though this is difficult to achieve in modern society. Anti-obesity drugs, as an alternative option, have side effects and are expensive [ 19 , 20 ]. Conversely, the habitual consumption of foods with anti-obesity effects may be a cost-effective and manageable way to suppress obesity.…”

Effects of acute administration of mazindol on brain energy metabolism in adult mice

“…Mazindol [5-(p-chlorophenyl)-2,4-dihydro-3H-imidazo(2,1-a)isoindol-5-ol] is an imidazo-isoindol derivative and chemically a non-amphetamine, tricyclic compound (7), with anorectic action, which suppresses feeding in both humans (8) and animals (9) by stimulating catecholaminergic systems (10). Mazindol is prescribed to reduce appetite and has been reported to be effective for obesity (11,12).…”